Tag: NTLA

Not many stocks are truly capable of generating a 1,000% return on investment within a reasonable time frame. Even so, a fair number of next-generation technology stocks have hit this lofty milestone over the years. In almost every case, the market woefully underestimated the company’s core value proposition ahead of…

7 June 2023 Three men who had heart failure caused by the build-up of sticky, toxic proteins are now free of symptoms after their condition spontaneously reversed in an unprecedented case described by a team at UCL and the Royal Free Hospital.  The condition, a form of amyloidosis affecting the…

Credit: SERGII IAREMENKO / Getty Images A little over a decade ago, a paper was published in Science1  that made science fiction a reality. Emmanuel Charpentier, Jennifer Doudna, and colleagues reported that they had identified a means of harnessing an element of a bacterial immune system to carry out genome…

Late-breaking presentation will include new safety, kallikrein reduction and attack rate data across all dose cohorts in the Phase 1 portion of the study Intellia to host investor webcast on Monday, June 12, at 8 a.m. ET CAMBRIDGE, Mass., May 31, 2023 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a…

Intellia Therapeutics to Present Updated Interim Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Hybrid Congress 2023 Late-breaking presentation will include new safety, kallikrein reduction and attack rate data across all dose cohorts in the Phase 1 portion of the…

Intellia Therapeutics, Inc., a clinical stage genome editing company, has seen a significant decrease in its short interest during the month of May. The short interest totalled 5,940,000 shares as of May 15th. This is a decrease of approximately 13% from the April 30th total of 6,830,000 shares. With an…

May 26, 2023 marks an important milestone for Intellia Therapeutics, Inc. (NASDAQ:NTLA), a biotechnology company that specializes in developing treatments using gene editing technology CRISPR/Cas9. The company’s latest earnings report had investors cautiously optimistic about the potential success of its pipeline of therapies. Notably, UBS Group AG also made headlines…

News Home Tuesday, May 16, 2023 12:47 PM | InvestorsObserver Analysts Mentioned in this article The market has been high on Intellia Therapeutics Inc (NTLA) stock recently. NTLA gets a Bullish score from InvestorsObserver Stock Sentiment Indicator. Intellia Therapeutics Inc has a Bullish sentiment reading. Find out what this means…

PRESS RELEASE Published May 17, 2023 DelveInsight’s, “CRISPR Therapies Pipeline Insight 2023” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in CRISPR Therapies pipeline landscape. It covers the CRISPR Therapies pipeline drug profiles, including CRISPR Therapies clinical trials and nonclinical stage products. It also covers the therapeutics…

The world is advancing at an unprecedented pace, with breakthrough technologies and innovations emerging to cater to the changing demands of consumers. One such sector that has caught the eye of investors and experts alike is the field of biotechnology. Among this highly lucrative sector, Intellia Therapeutics, Inc. (NASDAQ:NTLA) has…

PRESS RELEASE Published May 11, 2023 (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, CRISPR Therapies pipeline constitutes 25+ key companies continuously working towards developing 30+ CRISPR Therapies treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The CRISPR Therapies…

Intellia Therapeutics’ last quarterly earnings results were a testament to the company’s transformative approach towards medical treatment. The clinical stage genome editing firm, which uses the CRISPR/Cas9 system to develop curative therapeutics, reported impressive numbers that exceeded analyst expectations. Intellia Therapeutics posted an EPS of ($1.17) for the quarter, beating…

Only 10 years since Crispr made a splash as a possible therapeutic approach, the first product using Crispr/Cas9 gene editing is on the verge of approval. Vertex and Crispr Therapeutics’ exa-cel, for sickle cell anaemia and beta thalassaemia, has been filed with US and European regulators. Alongside this breakneck speed…

The ever-evolving world of medicine and biotechnology continues to grow every day. Such growth attracts investors seeking a piece of the pie, which leads to acquisition acts like the one we saw from &Moors & Cabot Inc. According to the Securities and Exchange Commission (SEC) recent filing by Moors &…

Forward-looking Information This Quarterly Report on Form 10-Q contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements may be…

CAMBRIDGE, Mass., May 01, 2023 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today released its 2023 Corporate Responsibility report. The report provides a comprehensive update of the Company’s performance and progress across key Environmental, Social…

Intellia Therapeutics: Revolutionary Genome Editing Techniques Intellia Therapeutics (NASDAQ:NTLA), the clinical stage genome editing company, is all set to release its quarterly earnings data before the market opens on Thursday, May 4th. This Boston-based biotech firm engages in developing curative therapeutics that fix disease-associated genes with a single treatment. What…

Gene editing stocks are one of the hottest sectors in medicine today. Genes are the foundation of life, and from creating new organisms to curing incurable diseases, the editing of genes can bring radical changes to life as we know it. That’s why CRISPR stocks that can edit genes have…

Institutional investor ProShare Advisors LLC has announced that it has increased its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 17.7% in the fourth quarter of the most recent fiscal year. According to the company’s latest filing with the Securities and Exchange Commission, ProShare Advisors now owns 18,735 shares of Intellia…

In this article, we will take a look at the 12 gene editing stocks with the best long-term potential. To see more such companies, go directly to 5 Gene Editing Stocks With the Best Long-Term Potential. Gene editing stocks are gaining ground on the back of an upbeat tone in…

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has been the subject of intense scrutiny by the financial analysts and market investors alike. The company, which is at the forefront of developing gene therapy treatments for genetic disorders using CRISPR/Cas9 technology, has garnered a consensus rating of “Moderate Buy” from twenty analysts as reported…

In this article, we discuss the top 10 CRISPR stocks to buy. If you want to see more stocks in this selection, check out Top 5 CRISPR Stocks To Buy.  Molecular biology, genetics, and genomics are in a significant period in history where technical capabilities and methods enable the editing…

Intellia Therapeutics, Inc. CAMBRIDGE, Mass., April 17, 2023 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced the appointment of Bill Chase, MBA, to its board of directors. Mr. Chase will be a member of…

PRESS RELEASE Published April 12, 2023 DelveInsight’s, “CRISPR Therapies Pipeline Insight 2023” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in CRISPR Therapies pipeline landscape. It covers the CRISPR Therapies pipeline drug profiles, including CRISPR Therapies clinical trials and nonclinical stage products. It also covers the therapeutics…

Gratus Capital LLC, a renowned hedge fund management firm, added to its impressive portfolio by announcing the acquisition of Intellia Therapeutics in a recent Form 13F filing with the Securities and Exchange Commission (SEC). According to the report, Gratus Capital purchased 67,311 shares of the company’s stock valued at approximately…

Pictured: Illustration of CRISPR-Cas9 editing DNA / iStock, Artur Plawgo Currently, there are no gene editing–based treatments on the market, but the technology continues its march toward potential FDA approval, with several products in mid- and late-stage trials. As these programs mature, 2023 could be a pivotal year for companies…

Pictured: Intellia office building with logo/company courtesy With several recent milestones, Intellia Therapeutics is setting a solid foundation for gene editing in rare diseases like hereditary angioedema (HAE) and transthyretin (ATTR) amyloidosis with an eye toward broader patient populations. Laura Sepp-Lorenzino, Ph.D., EVP and chief scientific officer, joined Intellia in…

Credit: S. Harris/Springer Nature Limited Vertex and CRISPR Therapeutics have submitted their CRISPR-based ex vivo cell therapy exagamglogene autotemcel (exa-cel) for FDA approval, for sickle cell disease (SCD) and beta-thalassemia. A regulatory decision on the gene-editing candidate is expected within 8 to 12 months. The companies have also filed for…

The CRISPR & Cas Genes market growth is driven by increasing number of clinical trials associates with CRIPR technology and rising of development of novel technologies. The CRISPR & Cas genes market revenue will reach at USD 8.96 billion by 2030 with a CAGR of around 17.03% from 2022 to…

Intellia Therapeutics (NASDAQ:NTLA) has recently received a rating downgrade by JPMorgan Chase & Co. The equities research firm reduced the price target of the company from $82.00 to $79.00. The current rating on this stock is “overweight,” indicating that it presents a favorable investment opportunity. The new price target predicts…

The nineteen analysts currently following Intellia Therapeutics, INC (NASDAQ: NTLA) have reportedly given the company’s shares a rating of “Moderate Buy” as the consensus recommendation for the investment strategy, as reported by Bloomberg.com. Investment professionals have made six recommendations regarding the stock: three to buy the stock, four to hold…

CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) —Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for NTLA-2002 for the treatment…

Amid yet another soft session on Wall Street, biotechnology firm Intellia Therapeutics (NASDAQ:NTLA) brightened the room considerably. Receiving a regulatory green light from the Food and Drug Administration (FDA), Intellia can now begin testing its CRISPR gene-editing technology in human patients. Naturally, NTLA stock jumped on the implications, initially popping…

The Food and Drug Administration has cleared Intellia Therapeutics to start human testing in the U.S. of an experimental CRISPR medicine for a rare swelling disorder, a sign the agency could be getting more comfortable with medicines that edit genes inside the body. Intellia on Thursday said the FDA will…

News Home Thursday, March 02, 2023 11:23 AM | InvestorsObserver Analysts Mentioned in this article The market has been high on Intellia Therapeutics Inc (NTLA) stock recently. NTLA gets a Bullish score from InvestorsObserver Stock Sentiment Indicator. Intellia Therapeutics Inc has a Bullish sentiment reading. Find out what this means…

alberto clemares expósito/iStock via Getty Images Investment Overview – Investors Struggle To Make Up Their Minds on Crispr Despite Sickle Cell Disease Approval Progress Studying the share price performance of Crispr Therapeutics (NASDAQ:CRSP) during the past five years, one thing seems clear – investors and the market can’t make up…

Our management’s discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements included in this Annual Report on Form 10-K, which have been prepared by us in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and…

The tech-heavy Nasdaq represents a collection of more risky stocks than the other major indexes and that is reflected by a poorer performance in bear markets and a better display during bull runs. But the risks associated with the Nasdaq are mere child play compared to edgier funds such as…

Natali_Mis Editas Medicine (NASDAQ:EDIT), Intellia Therapeutics (NASDAQ:NTLA), and Beam Therapeutics (NASDAQ:BEAM) were among clinical-stage biotechs to receive Overweight ratings at Cantor Fitzgerald as the firm launched its coverage on several gene editing companies. The analyst Rick Bienkowski sees multiple catalysts for gene editing companies at a time when the subsector…

According to the most recent filing that the company made with the SEC, the Teacher Retirement System of Texas increased its holdings in Intellia Therapeutics, Inc. (NASDAQ: NTLA) during the third quarter by 107.4 percentage points. As a result of the fund’s purchase of an additional 11,534 shares of the…

Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Rating) – Equities research analysts at SVB Leerink dropped their FY2022 earnings per share estimates for shares of Intellia Therapeutics in a research note issued on Monday, January 23rd. SVB Leerink analyst M. Foroohar now anticipates that the company will earn ($5.72) per share…

In the face of the bear market, biotechnology stocks have been performing better than the broader market, but Morningstar analysts say there are still plenty of undervalued stocks in this dynamic industry. That includes big names such as Moderna MRNA, which was in the spotlight for its coronavirus vaccine, and…

InvestorPlace – Stock Market News, Stock Advice & Trading Tips To many investors, gene editing sounds like the plot of a science fiction movie. The concept of being able to edit our DNA to cure genetic diseases is quite unbelievable, and the upside of gene editing to treat rare diseases…

Source: vxhal/ShutterStock.com Gene editing stocks present themselves as one of the more lucrative investments in the healthcare sector. Gene editing, a revolutionary take on the science of genetic engineering, has the potential to countless lives around the globe. By introducing genetic material into cells, scientists can correct genetic abnormalities in…

Thanks to a breakthrough in biotechnology made by two Nobel Prize-winning researchers in 2020, it will soon be possible to treat genetic diseases and cancer through selective gene sharing. The innovative method CRISPR/Cas9 it has also aroused interest among investors, thanks to which both Nobel laureates were able to create…

LOUISVILLE, Ky. — The future medical promise of CRISPR/Cas9 gene-editing appears to be a present-day reality for a small group of patients with the rare genetic condition known as hereditary angioedema (HAE). Interim results reported here from a phase I/II study involving 10 HAE patients showed a single infusion of…

Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses tested All patients treated in the 25 mg and 75 mg cohorts have an ongoing attack-free interval through latest follow-up First three patients treated have an ongoing attack-free interval of 5.5 – 10.6 months after a…

In vivo CRISPR/Cas9 editing of KLKB1 in patients with HAE Hilary Longhurst1, Lauré M. Fijen2, Karen Lindsay1, Carri Boiselle3, James Butler3, Adele Golden3, David Maag3, Joseph Vogel3, Yuanxin Xu3, and Danny M. Cohn2 1Auckland District Health Board and University of Auckland, New…

gorodenkoff/iStock via Getty Images The discovery of the CRISPR gene-editing tool has helped medical companies develop immunological defenses and curative systems against pathogens. Notable companies using this technology include CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), and Editas Medicine (NASDAQ:EDIT). Editas has an expansive pipeline under research. It includes Vivo gene-edited…

liulolo/iStock via Getty Images Investment Thesis If you had invested in the CRISPR / Cas9 gene editing pioneer Intellia Therapeutics (NASDAQ:NTLA) five years ago, you would likely be well satisfied with your return to date – a ~285% return on your investment – although you may also feel that it…

Serum TTR reductions were sustained at all doses tested with follow-up now reaching 12 months in the 0.1 and 0.3 mg/kg and six months in the 0.7 and 1.0 mg/kg cohorts Pharmacokinetic modeling and simulation indicated that an 80 mg fixed dose provides similar exposure to the 1.0 mg/kg dose,…

Last Price $ Last Trade Change $ Change Percent % Open $ Prev Close $ High $ low $ 52 Week High $ 52 Week Low $ Market Cap PE Ratio Volume Exchange NTLA – Market Data & News Trade Intellia Therapeutics Inc (NASDAQ: NTLA) shares are down 4.76%, or $2.65 per…

Andy/iStock via Getty Images Intellia Therapeutics (NTLA -3.1%) was upgraded by Brookline Capital Management to Buy from Hold with a $91 price target. Brookline analyst Leah Cann said the patent risk is unchanged, but the valuation has become attractive. In February, the U.S. Patent and Trademark Office backed the Broad…

The following are today’s upgrades for Validea’s Small-Cap Growth Investor model based on the published strategy of Motley Fool. This strategy looks for small cap growth stocks with solid fundamentals and strong price performance. EXLSERVICE HOLDINGS, INC. (EXLS) is a mid-cap growth stock in the Business Services industry. The rating…

Last Price $ Last Trade Change $ Change Percent % Open $ Prev Close $ High $ low $ 52 Week High $ 52 Week Low $ Market Cap PE Ratio Volume Exchange NTLA – Market Data & News Trade Intellia Therapeutics Inc (NASDAQ: NTLA), a Cambridge, Massachusetts, company,…

This story originally appeared on Zacks Editas Medicine, Inc. EDIT has made rapid progress in the development of its lead pipeline candidate, EDIT-101, which employs CRISPR gene editing, to treat Leber congenital amaurosis type 10 (LCA10) — a rare genetic illness that causes blindness. – Zacks The company is evaluating…

Last Price $ Last Trade Change $ Change Percent % Open $ Prev Close $ High $ low $ 52 Week High $ 52 Week Low $ Market Cap PE Ratio Volume Exchange NTLA – Market Data & News Trade Intellia Therapeutics Inc (NASDAQ: NTLA), a Cambridge, Massachusetts, company,…

September 17, 2021 1 min read ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . “ data-action=”subscribe”> Subscribe We were unable to process…

Courtesy Intellia Therapeutics Intellia Therapeutics is celebrating another first today as the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for NTLA-5001, its first wholly-owned ex vivo CRISPR genome editing candidate. NTLA-5001 is being developed for the treatment of acute myeloid leukemia (AML). Intellia…

Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia Details Category: DNA RNA and Cells Published on Thursday, 16 September 2021 17:52 Hits: 130 NTLA-5001 is Intellia’s first ex vivo candidate using its proprietary cell engineering…

Last Price $ Last Trade Change $ Change Percent % Open $ Prev Close $ High $ low $ 52 Week High $ 52 Week Low $ Market Cap PE Ratio Volume Exchange NTLA – Market Data & News Trade Intellia Therapeutics Inc (NASDAQ: NTLA), a Cambridge, Massachusetts, company,…

Therapeutic applications of genome editing were envisioned at least as early as the mid-1990s, when the first sequence-specific genome editing technologies emerged. Initially, such applications were considered distant prospects, but by 2012, they suddenly seemed near to hand. It was at that time that CRISPR technologies emerged. CRISPR, which stands…

Photo courtesy of Intellia Therapeutics Sports fans know that nothing is better for the chemistry of a team than winning, and on the CRISPR field, Intellia Therapeutics is on a winning streak.    On June 26, Intellia set the biotech world on fire, announcing the first-ever clinical data supporting the safety…

Last Price $ Last Trade Change $ Change Percent % Open $ Prev Close $ High $ low $ 52 Week High $ 52 Week Low $ Market Cap PE Ratio Volume Exchange NTLA – Market Data & News Trade Intellia Therapeutics Inc (NASDAQ: NTLA) shares fell 5.48%, or $8.36…

Broadcast Date: September 16, 2021Time: 8 am PT, 11 am ET, 17:00 CET When CRISPR-Cas9 gene-editing technology exploded onto the life science stage almost a decade ago, it was widely touted as a potentially curative therapy for many genetic diseases, using various ex vivo and in vivo delivery methods. That promise is…

Unlike most other CRISPR/Cas-9 therapies that are ex vivo treatments in which cells are modified outside the body, this study was successful with an in vivo treatment Use of CRISPR-Cas9 gene editing technology for therapeutic purposes can be a boon for clinical laboratories. Not only is this application a step…

Shares of Editas Medicine, Inc. EDIT have rallied 78.7% in the past three months compared with the industry’s increase of 7.4%. Zacks Investment Research Image Source: Zacks Investment Research The company has made rapid progress in the development of its lead pipeline candidate, EDIT-101, in this time frame. EDIT-101 employs…

By BRUCE KAMICH Aug 12, 2021 | 12:31 PM EDT Stocks quotes in this article: NTLA, IWM, AMC Intellia Therapeutics Inc. (NTLA)  is one of the largest holdings in the iShares Russell 2000 exchange-traded fund  (IWM)  and one Real Money subscriber wonders if this stock can help the IWM break out…